The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension contribute markedly to the global burden of chronic respiratory disease. Despite this, the burden of pulmonary vascular diseases remains underestimated, and the significance of pulmonary vascular disease merits greater attention from the medical community.
Assembly 13 has two Groups:
Group 13.02
Chair: Luis Jara-Palomares
Secretary: Nesrin Öcal
Pulmonary embolism (PE) is the third leading cause of cardiovascular death, after acute myocardial infarction and stroke.
Our Group is dedicated to the diagnosis, risk stratification, treatment of the acute phase of PE and follow-up. Our objectives are focused on training and research, identifying areas of interest to improve the care of our patients. In the acute situation of the thrombotic event, it is crucial to carry out an adequate risk stratification to adapt the care to the patient's risk of suffering complications. In the follow-up of the patient with PE, the risk of recurrence, the risk of bleeding, as well as other factors and variables to be considered (search for occult neoplasia, identification of other cardiovascular risk factors, identify the profile of patients who benefit from thrombophilia testing, sports activities after the thrombotic event, etc.). This Group is dynamic and wants to incorporate anyone who is interested in any of the facets of this disease (acute or follow-up), and from the point of view of training or research.
Joining our Group provides a direct connection to clinicians, academics and researchers working in this field.
Join this assembly
You can join this assembly by selecting it as your main group or one of your optional groups in myERS. Only ERS members can join this assembly. Selections can be changed at any time.
